Cytek Biosciences Stock Market Value
| CTKB Stock | USD 4.36 0.05 1.16% |
| Symbol | Cytek |
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytek Biosciences. Projected growth potential of Cytek fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Cytek Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.735 | Earnings Share (0.11) | Revenue Per Share | Quarterly Revenue Growth 0.015 | Return On Assets |
Investors evaluate Cytek Biosciences using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Cytek Biosciences' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Cytek Biosciences' market price to deviate significantly from intrinsic value.
It's important to distinguish between Cytek Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cytek Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Cytek Biosciences' market price signifies the transaction level at which participants voluntarily complete trades.
Cytek Biosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Cytek Biosciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Cytek Biosciences.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in Cytek Biosciences on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding Cytek Biosciences or generate 0.0% return on investment in Cytek Biosciences over 90 days. Cytek Biosciences is related to or competes with Varex Imaging, Avanos Medical, Standard Biotools, Clearpoint Neuro, Treace Medical, CeriBell, and Orthopediatrics Corp. Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific adv... More
Cytek Biosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Cytek Biosciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Cytek Biosciences upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.04 | |||
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 29.07 | |||
| Value At Risk | (4.99) | |||
| Potential Upside | 5.95 |
Cytek Biosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cytek Biosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Cytek Biosciences' standard deviation. In reality, there are many statistical measures that can use Cytek Biosciences historical prices to predict the future Cytek Biosciences' volatility.| Risk Adjusted Performance | 0.0119 | |||
| Jensen Alpha | (0.12) | |||
| Total Risk Alpha | (0.48) | |||
| Sortino Ratio | (0.03) | |||
| Treynor Ratio | 0.007 |
Cytek Biosciences February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0119 | |||
| Market Risk Adjusted Performance | 0.017 | |||
| Mean Deviation | 2.66 | |||
| Semi Deviation | 3.0 | |||
| Downside Deviation | 3.04 | |||
| Coefficient Of Variation | 20953.54 | |||
| Standard Deviation | 4.16 | |||
| Variance | 17.34 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | (0.12) | |||
| Total Risk Alpha | (0.48) | |||
| Sortino Ratio | (0.03) | |||
| Treynor Ratio | 0.007 | |||
| Maximum Drawdown | 29.07 | |||
| Value At Risk | (4.99) | |||
| Potential Upside | 5.95 | |||
| Downside Variance | 9.24 | |||
| Semi Variance | 8.97 | |||
| Expected Short fall | (3.27) | |||
| Skewness | 2.14 | |||
| Kurtosis | 8.86 |
Cytek Biosciences Backtested Returns
Cytek Biosciences secures Sharpe Ratio (or Efficiency) of -0.0984, which signifies that the company had a -0.0984 % return per unit of risk over the last 3 months. Cytek Biosciences exposes twenty-eight different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Cytek Biosciences' Mean Deviation of 2.66, downside deviation of 3.04, and Risk Adjusted Performance of 0.0119 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.42, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cytek Biosciences will likely underperform. At this point, Cytek Biosciences has a negative expected return of -0.33%. Please make sure to confirm Cytek Biosciences' expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to decide if Cytek Biosciences performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.38 |
Below average predictability
Cytek Biosciences has below average predictability. Overlapping area represents the amount of predictability between Cytek Biosciences time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Cytek Biosciences price movement. The serial correlation of 0.38 indicates that just about 38.0% of current Cytek Biosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.38 | |
| Spearman Rank Test | 0.43 | |
| Residual Average | 0.0 | |
| Price Variance | 0.14 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cytek Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cytek Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytek Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytek Biosciences Stock:Check out Cytek Biosciences Correlation, Cytek Biosciences Volatility and Cytek Biosciences Performance module to complement your research on Cytek Biosciences. For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Cytek Biosciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.